Aspira Women’s Health, Inc. to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:00 AM ET. The presentation will be webcast live, with registration details available on their website. Aspira is focused on innovative testing for women’s health, specifically in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes FDA-cleared options like OVA1® and OVERA®. The company aims to address ethnic disparities in health outcomes through advanced bioanalytical solutions.

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it has been invited to present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, taking place Thursday, November 19, 2020.

Aspira Women’s Health is scheduled to present on Thursday, November 19^th at 9:00amET. The presentation will be webcast live and available for replay. Registration to view a webcast of  the presentation can be found at: https://wsw.com/webcast/canaccord44/awh/2242496.

This conference is open only to clients of Canaccord Genuity.

To receive additional information about Canaccord Genuity, please contact Nadine Miller, Managing Director, Global Head of Marketing & Communications at nmiller@cgf.com.

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as, Vermillion inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1^® plus includes our FDA-cleared products, OVA1^® and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

 

FAQ

When is Aspira Women’s Health scheduled to present at the Canaccord Genuity Forum?

Aspira Women’s Health is scheduled to present on November 19, 2020, at 9:00 AM ET.

How can I watch the Aspira Women’s Health presentation?

The presentation will be webcast live, and you can register to view it on Aspira's website.

What is the main focus of Aspira Women’s Health?

Aspira Women’s Health focuses on innovative testing options and bioanalytical solutions for women's health, particularly in ovarian cancer risk assessment.

What products does Aspira Women’s Health offer?

Aspira offers FDA-cleared products like OVA1® and OVERA® for ovarian malignancy risk detection.

What is the significance of the Canaccord Genuity Virtual MedTech & Diagnostics Forum for Aspira?

The forum provides Aspira Women’s Health a platform to showcase its advancements and innovations in women's health and diagnostics.